Related Experiment Video
Updated: Dec 8, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
Nikolaos I Kanellakis1,2,3,4, Rachelle Asciak5,2,4, Megat Abd Hamid6,7
1Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom nikolaos.kanellakis@ndm.ox.ac.uk.
Abstract:
Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM.
Insights
Patient-derived cell cultures offer a new way to study malignant pleural mesothelioma (MPM), an aggressive cancer. These models show tumor diversity and drug responses, aiding research into better MPM treatments.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis.
- Existing models may not fully capture MPM's complexity and heterogeneity.
Purpose of the Study:
- To evaluate the feasibility of using patient-derived cell cultures as an ex vivo model for MPM.
- To assess the utility of these models in drug screening and immunotherapy research.
Main Methods:
- Established and characterized 16 patient-derived MPM cell cultures.
- Performed high-throughput drug screening and co-culture assays with cytotoxic T cells.
- Investigated neoantigen processing and presentation capabilities.
Main Results:
- MPM cell cultures demonstrated stemness features and reflected intra- and inter-patient heterogeneity.
- Diverse drug responses and T cell interactions were observed in the cell cultures.
- Biphasic MPM cells showed endogenous processing and presentation of the SSX-2 neoantigen.
Conclusions:
- Patient-derived MPM cell cultures represent a feasible and faithful ex vivo model.
- These models hold promise for advancing MPM research, drug development, and understanding treatment responses.
